Galimedix Therapeutics initiates phase 1 trial of oral GAL-101
Author(s): David Hutton Key Takeaways GAL-101 targets misfolded amyloid beta monomers, preventing toxic oligomer and protofibril formation, with potential applications in Alzheimer’s, dry AMD, and glaucoma. The Phase 1 trial…